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ABSTRACT
Interferon (IFN) regulatory factor-1 (IRF-1) and IRF-2 play opposing roles in the regulation of many IFN-
g-inducible genes. To investigate the signal transduction pathway in response to IFN-g in light of differences
in growth effects, we selected four human breast carcinoma cell lines based on a spectrum of growth inhibi-
tion by IFN-g. MDA468 growth was markedly inhibited by IFN-g, and it showed substantial induction of
IRF-1 mRNA but little IRF-2 induction. SKBR3 showed little growth inhibition and little induction of IRF-1
mRNA but significant induction of IRF-2 mRNA. HS578T and MDA436 growth inhibition and IRF-1/IRF-2
induction were intermediate. All four cell lines showed intact receptor at the cell surface and Stat1 translo-
cation to the nucleus by immunostaining. By EMSA, there were marked differences in the induced ratio of
IRF-1 and IRF-2 binding activity between the cell lines that correlated with growth inhibition. Finally, anti-
sense oligonucleotides specific for IRF-1 attenuated IFN-g growth inhibition in MDA436 and MDA468, con-
firming the direct role of IRF-1 in IFN-g growth inhibition. Induction of IRF-1 causes growth inhibition in
human breast cancer cell lines, and induction of IRF-2 can oppose this. The relative induction of IRF-1 to
IRF-2 is a critical control point in IFN-g response.
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INTRODUCTION
INTERFERON (IFN) REGULATORY FACTORS 1 AND 2 (IRF-1 andIRF-2) are nuclear transcription factors that bind the same
DNA sequence in the promoter regions of genes known to be
induced by IFNs. However, IRF-1 is a transcriptional activator
to upregulate gene expression, and IRF-2 generally appears to
downregulate, or block upregulation, of the same genes. Al-
though viruses, dsRNA, and type I IFNs were initially found to
induce IRF-1 production, IFN-g has been found to be the most
reliable and powerful inducer of IRF-1.(1–3) IRF-1 mediates sev-
eral IFN-g effects on cells, including (1) inducible nitric oxide
synthase (iNOS) expression by macrophages,(4,5) (2) guanylate
binding protein (gbp) expression,(6) (3) MHC class I expres-
sion,(7–9) (4) MHC class II expression,(10–12) and (5) IFN-a/b
expression.(9,13,14) More recently, IRF-1 has also been impli-
cated in the upregulation of Fas ligand in T cells(15) and cy-
clooxygenase-2 (COX-2) in macrophages.(16) IRF-2 is induced
later than IRF-1 and appears to have greater protein stability.(17)
Therefore, IRF-2 may play a role in feedback inhibition of IFN-
g effects mediated by IRF-1, and the ratio of IRF-1/IRF-2 may
be critical for determining the cellular response to IFN-g.
The two IRF proteins also appear to have opposing roles in
the regulation of cell growth and tumorigenicity. NIH3T3 cells
overexpressing the IRF-2 gene became transformed and were
more tumorigenic in nude mice, implicating IRF-2 as a poten-
tial oncoprotein.(18) In contrast, IRF-1 overexpression in the
IRF-2-transformed cells reversed this phenotype, implicating
IRF-1 as a tumor suppressor.(18) Similarly, embryonic fibro-
blasts from knockout mice lacking IRF-1 were transformed by
introduction of the c-Ha-ras oncogene, whereas normal cells
were not. This was reversed by IRF-1 gene transfection.(19) Pre-
viously, we demonstrated that IRF-1 overexpression in MCA
101 cells can suppress the malignant phenotype and enhance
immunogenicity in syngeneic mice.(12) In addition, the chro-
mosomal region containing the IRF-1 gene is deleted in some
patients with leukemia or myelodysplastic syndromes,(20) gas-
tric adenocarcinomas,(21) and esophageal carcinomas,(22) sug-
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gesting a possible tumor suppressor role for IRF-1 in human
cancer.
Data from our laboratory are consistent with the involvement
of this pathway in the development and progression of human
cancer. We showed progressive loss of IRF-1 expression with
more advanced melanoma, as judged by morphology, thickness,
and stage.(23) Thicker lesions and nodular lesions are more
likely to have lost IRF-1 expression, compared with more fa-
vorable lesions. Human breast cancers showed frequent loss of
IRF-1 and gain of IRF-2 expression with in situ and invasive
lesions, which also correlates with the likelihood of axillary
lymph node involvement.(24) This was substantially different
from the nearly universal expression of IRF-1 and rare expres-
sion of IRF-2 in normal breast tissue.
To evaluate the role of this pathway in endogenous control
of tumor growth, we have used murine models. With RT-PCR,
we have shown that IRF-1 and IRF-2 expression patterns are
consistent with opposing roles in IFN-g growth inhibition in
murine tumor cells in vitro, with IRF-1 correlating with inhi-
bition of growth and IRF-2 opposing inhibition.(25) In particu-
lar, the growth of the mouse melanoma cell line B16-F10 was
markedly inhibited by IFN-g, and the cell line showed almost
no IRF-2 induction by RT-PCR. We have also demonstrated
that IRF-2 overexpression in B16-F10 cells can increase tu-
morigenicity in syngeneic mice by both increased rate of cell
growth and increased resistance to IFN-g.(26)
Although we have significant data to support the role of IRF-
1 and IRF-2 in IFN-g-mediated growth inhibition in the mouse
model, there have been very few studies assessing the role of
IRF-1 and IRF-2 in IFN growth inhibition in human cancer
cells. In fact, two studies have been unable to find a correla-
tion of IRF-1 and IRF-2 with type I IFN response or lack of re-
sponse in human cancer cells,(27,28) although no study has been
performed to date for IFN-g. IFN-g has significant antitumor
activity and has been shown to play an important role in the
antitumor activity of other cytokines, including tumor necrosis
factor-a (TNF-a) and interleukin-12 (IL-12). We and others
have shown that endogenous IFN-g appears to play a role in
suppression of some tumors. Conversely, how tumors respond
to IFN-g may play a critical role in tumor progression. In this
study, we analyzed four human breast carcinoma cell lines with
a spectrum of growth inhibitory responses to IFN-g for IRF-1
and IRF-2 induction at the level of mRNA and protein binding
activity using RT-PCR and electrophoretic mobility shift assay
(EMSA). We then evaluated the role of IRF-1 in mediating the
IFN-g growth effects with antisense techniques.
MATERIALS AND METHODS
Human breast cancer cell lines
The human breast cell lines BT20 (BT-20), SKBR3 (SK-BR-
3), HS578T, MDA436 (MDA-MB-436), MDA468 (MDA-MB-
468), ZR75-1 (ZR-75-1), and T47D (T-47D) were obtained
from American Type Culture Collection (Rockville, MD).
T47D and HS578T were cultured in vitro in DMEM medium
supplemented with 10% fetal bovine serum (FBS), L-glutamine,
penicillin/streptomycin, and gentamicin (DMEM-CM). BT20,
MDA468, and MDA436 were cultured in DMEM-CM and
Ham’s F12 medium mixed in a 1:1 ratio. SKBR3 and ZR75-1
were cultured in RPMI 1640 supplemented with 10% FBS, L-
glutamine, penicillin/streptomycin, and gentamicin. All cells
were incubated at 37°C at 5% CO2.
Assay of cell growth in vitro
Cells were plated in 200 ml of appropriate medium in the in-
ner 60 wells of 96-well plates at 2 3 103 cells/well, either in
the presence or absence of 100 U/ml recombinant human IFN-
g (PharMingen, San Diego, CA). MTT (5 mg/ml) (Sigma, St.
Louis, MO) was added at 20 ml/well to triplicate wells daily.
After 24 h incubation with MTT, the medium was removed
from the triplicate wells. The formazan crystals were allowed
to air dry before being dissolved in mineral oil (50 ml/well)
(Schnucks Markets, Bridgeton, MO). Absorbance was mea-
sured at 595 nm on a microplate reader (Bio-Rad, Richmond,
CA).
Detection of mRNA
Subconfluent cells were trypsinized and washed in phosphate-
buffered saline (PBS) and frozen at 270°C. mRNA was isolated
from cells using detergent lysis and oligo dT spun columns (Mi-
cro-FastTrack™kit, Invitrogen, San Diego, CA). cDNA was pre-
pared by RT reaction of identical amounts of isolated mRNA
(RT-PCR kit, Stratagene, La Jolla, CA). Equivalent amounts of
cDNA were amplified by PCR for assessment of human 
IRF mRNA expression using the primers 59-AGATCCCATG-
GAAGCATGCTG-39 (sense) and 59-CCTGGAACTGTGTA-
GCTGC-39 (antisense) for human IRF-1 and 59-CAAGTGGCT-
TAACAAGG-39 (sense) and 59-GGACCGCATACTCAGG-
AG-39 (antisense) for human IRF-2. PCR buffer (10 mM KCl,
10 mM (NH4)2SO4, 20 mM Tris-HCl, pH 8.8, 2 mM MgSO4,
0.1% Triton X-100 [New England BioLabs, Beverly, MA]),
dNTPs (GIBCO-BRL, Gaithersburg, MD), primers, and VentR
polymerase (New England BioLabs) were added, followed by 30
cycles at 94°C for 50 sec, 55°C for 50 sec, 72°C for 60 sec. Am-
plified product (8 ml) was separated by electrophoresis on 0.7%
agarose minigels and stained with ethidium bromide. Although
no quantitative measurements of mRNA production can be made
from this method of RT-PCR, qualitative assessments of differ-
ences in degree of production can be made from obvious differ-
ences in band intensity, as identical amounts of cDNA were used
for PCR and identical amounts of PCR product were run on the
gels. No comparisons can be made between products from dif-
ferent primers. The primers for cyclophilin, 59-CGTGT-
GAAGTCACCACCCT-3 9 (sense) and 59-ATGGTCAACCC-
CACCGTGTT-39 (antisense), were generous gifts from Dr.
Jeffrey Moley (Washington University, St. Louis, MO) and were
used in all cases as an internal control.
Flow cytometry
Subconfluent cells were trypsinized, washed, and directly
treated with FITC-labeled antihuman IFN-g receptor monoclo-
nal antibody mAb (Serotec, Raleigh, NC). FITC-labeled irrel-
evant Ab was used as a control. All incubations and subsequent
washes were performed in PBS containing 3% neonatal calf
serum and 0.1% sodium azide. Cells were analyzed with a FAC-
Scan flow cytometer (Becton Dickinson, Mountain View, CA).
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Stat1 immunohistochemistry
Cells were grown on chamber slides (Nunc, Inc., Naperville,
IL) in appropriate medium for 24 h in a 37°C sterile incubator.
After coincubation with 100 U/ml IFN-g or control for 1 h, the
cells were briefly washed with PBS and subsequently fixed with
freshly prepared 3% formaldehyde/PBS, pH 7.4, for 10 min.
Permeabilization was performed with 1% Triton-X 100 for 2
min, followed by washes with 0.1% Tween 20/PBS. Nonspe-
cific binding of the secondary antibody was blocked with 2%
bovine serum albumin (BSA) in PBS for 1 h at ambient tem-
perature. The Stat1 primary antibody was a generous gift from
Chris Schindler (Columbia University, New York, NY). It is a
rabbit polyclonal antibody raised against a GST fusion protein
encoding the last 36 amino acids of human Stat1. This poly-
clonal antibody at 1:500 titer was incubated overnight at 4°C
in a rotating, humidified chamber. After rinsing with PBS, a
secondary antibody conjugated to Cy3 (goat antirabbit-Cy3,
H 1 L) (Jackson Immunology, West Grove, PA) was incubated
for 15 min at ambient temperature. Excess secondary antibody
was rinsed off, and a slow fade mounting medium, DABCO in
glycerol (Sigma), was covered with glass coverslips. The slides
were analyzed with a confocal laser scanning microscope
equipped with an argon/krypton ion laser and were sectioned
at 0.5-mm intervals in the 512 3 512 pixel format. To deter-
mine background nonspecific staining, a negative control was
performed without primary antibody incubation. No binding
was observed.
EMSA
Whole cell extracts were obtained from trypsinized subcon-
fluent monolayers of cells and prepared as described by Harada
et al.(13) Briefly, pelleted cells were suspended in 4 3 vol lysis
buffer (20 mM HEPES, pH 7.9, 50 mM NaCl, 10 mM EDTA,
2 mM EGTA, 10 mM molybdate, 10 mM vanadate, 100 mM
NaF, 0.1% NP40, 0.5 mM PMSF, 100 mg/ml leupeptin), soni-
cated for 2 min, and centrifuged at 10,000 rpm for 10 min. The
supernatant was used as cell extract. Extracts (15 mg/sample)
were mixed with 32P-labeled C13 oligomer (,1.5 pmol/sam-
ple, 50,000–200,000 cpm/sample; sequence derived from Fu-
jita et al.(29) specifically binds IRF-1 and IRF-2), 1 mg herring
sperm DNA, and 2 mg poly(dI:dC) and incubated at 25°C for
60 min in a final volume of 10 ml buffer containing 10 mM
Tris-HCl, pH 7.5, 50 mM NaCl, 1 mM DTT, 1 mM EDTA, and
5% glycerol. Alternatively, 1.75 pmol unlabeled C13 was added
to each sample for competition experiments. Some extracts
were preincubated with 1 ml antibody (anti-IRF-1 or anti-IRF-
2, 1 mg/ml) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA)
at 0°C for 60 min before mixing with oligomer. The IRF-1 an-
tibody is an affinity-purified rabbit polyclonal antibody raised
against a peptide representing amino acids 306–325 of the car-
boxyl-terminus. This antiserum is not cross-reactive with IRF-
2 or IFN-stimulated gene factor 3g (ISGF3g). The IRF-2 anti-
body is an affinity-purified rabbit polyclonal antibody raised
against a peptide corresponding to amino acids 331–348 map-
ping at the carboxy-terminus and does not cross-react with IRF-
1 or ISGF3g. Because these antibodies are specific for the car-
boxy-terminus, they do not interfere with DNA binding and
create supershifted complexes forming bands of intensity on au-
toradiographs correlating with the amount of protein bound to
the radiolabeled oligonucleotide probe. The samples were run
on preelectrophoresed nondenaturing 4% polyacrylamide gels
and autoradiographed.
Antisense oligonucleotide experiments
The phosphorothioate antisense oligonucleotide against IRF-1
(IRF-1 AS) was synthesized (Oligos Etc. Inc., Wilsonville, OR)
with the sequence 59-CGAGTGATGGGCATGTTGG C-39 for
targeting the translation initiation site in human IRF-1 mRNA.
This sequence was obtained from Sato et al.(30) and has been
shown to markedly decrease IRF-1 protein levels by im-
munoblotting and IRF-1 mRNA by RT-PCR. A nonspecific phos-
phorothioate oligonucleotide with the sequence 59-TGGATCC-
GACATGTCAGA-39 (NS, Oligos Etc. Inc.) was used as a control.
Cells in log phase growth at 30%–50% confluency in 96-
well plates were cultured with IRF-1 AS, NS, or no oligo in
varying concentrations in reduced serum medium (Opti-MEM,
GIBCO-BRL) at 100 ml/well. Four hours later, 100 ml Opti-
MEM with identical concentrations of oligonucleotide with or
without IFN-g at 200 U/ml was added in triplicate to give a fi-
nal concentration of 100 U/ml IFN-g. Four to five days later,
MTT was used to assay viable cell number. Alternatively, cells
were plated in 6-well plates with oligonucleotide or no oligo at
1 ml/well. Four hours later, 1 ml Opti-MEM with identical con-
centrations of oligonucleotide with IFN-g at 200 U/ml was
added, and 2 days later, cells were harvested for EMSA.
RESULTS
Assessment of growth inhibition and IRF-1 and IRF-2
mRNA expression by RT-PCR in seven human breast
carcinoma cell lines
We initially performed growth assays and RT-PCR for IRF-
1 and IRF-2 mRNA expression on seven human breast carci-
noma cell lines to define the most heterogeneous group of cell
lines in growth inhibitory response to IFN-g. We then assessed
the possibility of correlation of IRF-1 and IRF-2 expression
with the response, understanding the limitations and qualitative
nature of RT-PCR (Fig. 1). SKBR3 showed almost no inhibi-
tion of growth with 100 U/ml IFN-g incubation, whereas
MDA468 showed tremendous inhibition of growth. BT20,
HS578T, ZR75-1, MDA436, and T47D all had an intermediate
response to IFN-g in terms of growth inhibition. Growth inhi-
bition was not significantly changed in any cell line, including
SKBR3, by an increase to 1000 U/ml IFN-g (data not shown).
The growth inhibition correlated with the assessed IRF-1
mRNA expression by RT-PCR, with SKBR3 showing the least
expression of IRF-1 mRNA and MDA468 showing the most.
Other cell lines had intermediate levels of IRF-1 mRNA by RT-
PCR. Furthermore, SKBR3 also showed clearly increased IRF-
2 mRNA by RT-PCR, whereas all the other cell lines showed
barely detectable levels of IRF-2 mRNA.
Correlation of IRF-1 and IRF-2 mRNA expression by
RT-PCR with growth inhibitory response to IFN-g in
four human breast carcinoma cell lines
In Figure 2, we show the entire pattern of growth inhibition
by IFN-g on the four human breast carcinoma cell lines we
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chose for further study, the full time course of induced IRF-1
and IRF-2, and control cyclophilin mRNA expression by RT-
PCR. MDA468, which clearly showed the greatest inhibition
and possibly even a cytotoxic response to IFN-g, also showed
the earliest and greatest induction of IRF-1 mRNA by RT-PCR.
SKBR3, which showed almost no growth inhibition, also
showed very little induction of IRF-1 mRNA by RT-PCR and
also showed clearly detectable IRF-2 mRNA at 24 h. HS578T
and MDA436, which showed intermediate growth inhibition by
IFN-g, also showed intermediate levels of IRF-1 mRNA.
Assessment of IFN-g receptor presence 
and Stat1 translocation
SKBR3 resistance to growth inhibition and poor expression
of IRF-1 by RT-PCR in response to IFN-g could be explained
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FIG. 1. Assessment of IFN-g growth inhibition and IRF-1 and IRF-2 mRNA expression by RT-PCR in seven human breast
carcinoma cell lines. Each cell line was plated at 2 3 103 cells/well on 96-well plates in appropriate medium with or without 100
U/ml IFN-g. MTT was applied to wells daily in triplicate. The medium was aspirated the next day, and at the end of the exper-
iment, tetrazolium crystals dissolved in mineral oil and wells read on a spectrophotometer. The bar graph depicts the percentage
inhibition of growth after 9 days of incubation. For RT-PCR, each cell line was plated at 5 3 105 cells/well on 6-well plates in
appropriate medium and allowed to adhere overnight. Cells were treated with 100 U/ml IFN-g the next day. After 0.5, 1, 6, and
24 h of treatment, cells were trypsinized, mRNA was obtained using spun oligo dT columns, and RT-PCR was performed using
specific primers for IRF-1 and IRF-2. The intensity and earliest point of induction correlated with each other and were subjec-
tively assessed to determine the level of expression, which is designated by the number of 1 signs (1 to 11111).
FIG. 2. IFN-g growth inhibition and IRF-1 and IRF-2 mRNA expression by RT-PCR in four human breast carcinoma cell lines.
Cells were assessed for growth and IRF-1 and IRF-2 mRNA expression in response to IFN-g as detailed in the Figure 1 legend.
(Top) Entire pattern of growth inhibition in four cell lines by the growth assay detailed in the Figure 1 legend. (Bottom) Full
time course of IRF-1 and IRF-2 and cyclophilin (Cyclo) mRNA expression by RT-PCR performed as detailed in the Figure 1
legend.
by low levels or absence of IFN-g receptor. However, SKBR3
clearly has significant levels of IFN-g receptor on the cell sur-
face, as assessed by flow cytometry (data not shown). Alterna-
tively, SKBR3 resistance to growth inhibition and low IRF-1
expression could also be due to signal transduction defects prox-
imal to IRF-1. In particular, Stat1 translocation to the nucleus
is a critical event in IFN-g signal transduction.(31,32) In fact, de-
fects at the level of Stat1 have been reported in IFN-resistant
human melanoma cells.(33) However, each cell line, including
MDA468 and SKBR3, showed translocation of Stat1 to the nu-
cleus after stimulation with 100 U/ml IFN-g for 1 h, as dem-
onstrated by immunohistochemistry, with clear nuclei in the un-
stimulated cells changing to nuclear staining in the presence of
IFN-g (Fig. 3).
Expression of IRF proteins in response to IFN-g
by EMSA
We performed EMSA to analyze IRF-1 and IRF-2 induction
by IFN-g in the four human breast carcinoma cell lines for sev-
eral reasons: (1) EMSA measures protein binding to a specific
consensus sequence and thus identifies not only protein but also
functionality or activity to the extent of DNA binding. (2)
EMSA with IRF-1 or IRF-2 antibody and densitometry allows
for relative quantitation between different cell lines and differ-
ent treatments and for comparison between IRF-1 and IRF-2
protein expression. This has been an accepted method of anal-
ysis of EMSA results.(14,18) (3) EMSA does not suffer from cer-
tain technical limitations as does RT-PCR, such as variable re-
sults with different primers. The radiolabeled C13 oligomer
binds both IRF-1 and IRF-2 but binds no other known DNA-
binding proteins. Our initial studies were performed without an-
tibodies to evaluate overall IRF induction by IFN-g in the four
human breast carcinoma cell lines (Fig. 4). There were low lev-
els of baseline IRF seen in all four cell lines that were markedly
increased by incubation with 100 U/ml and 250 U/ml IFN-g
for 2 days. Clearly, IFN-g signal transduction is intact down to
this level. However, there was no correlation between this re-
sponse and the level of growth inhibition. SKBR3, which
showed almost no growth inhibition, has a significant response
in IRF production, whereas HS578T has the least IRF response
(Fig. 3).
When we used antibodies to distinguish IRF-1 and IRF-2,
we found marked differences in the ratio of IRF-1/IRF-2 after
IFN-g stimulation, and this ratio correlated with IFN-g inhibi-
tion of growth (Fig. 5 compared with Fig. 2). These relation-







FIG. 3. IFN-g-induced translocation of Stat-1 from the cytoplasm to the nucleus. Cells were grown overnight on chamber slides
before coincubation with 100 U/ml IFN-g or control for 1 h. Permeabilization was performed with 1% Triton-X 100 for 2 min.
Incubation with an anti-Stat1 primary antibody was followed by a secondary antibody conjugated to Cy3. The slides were ana-
lyzed with a confocal laser scanning microscope. (A) MDA468 without IFN-g exposure. (B) MDA468 after 1 h IFN-g exposure.
(C) SKBR3 without IFN-g exposure. (D) SKBR3 after 1 h IFN-g exposure.
ships were confirmed in repeated experiments, using either or
both IRF-1 antibody and IRF-2 antibody to distinguish the two
proteins, whether comparing supershifted with unshifted com-
plex, supershifted with supershifted complex, or unshifted with
unshifted complex. MDA468 had the greatest inhibitory re-
sponse to IFN-g and had the highest ratio of IRF-1/IRF-2.
HS578T and MDA436 had an intermediate inhibitory response
to IFN-g and had intermediate IRF-1/IRF-2 ratios. SKBR3 had
almost no response to IFN-g and had the lowest ratio (Fig. 5).
We also performed Western blots using the IRF-1 and IRF-2
antibodies in SKBR3 and MDA468, with results consistent with
EMSA (data not shown), but as stated previously, there is no
way to compare the ratios of IRF-1/IRF-2 using different anti-
bodies with Western blot, as is achievable with EMSA.
To further define these marked differences in the ratios af-
ter IFN-g stimulation, we compared the induction of IRF-1
binding activity and IRF-2 binding activity of each cell line af-
ter incubation with IFN-g. As shown in Figure 6, unstimulated
cells showed little or no IRF-1-binding activity, but when in-
cubated with 100 U/ml IFN-g for 2 days, there was a marked
induction of IRF-1, correlating with the mRNA expression data
by RT-PCR (Fig. 2). SKBR3 had clear induction of IRF-1, but
it is the least of all the cell lines, whereas MDA468 produced
the greatest IRF-1 binding activity.
IRF-2 binding activity decreased in response to IFN-g in the
three cell lines that showed an inhibitory response to IFN-g,
and SKBR3 showed increased IRF-2 binding activity in re-
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FIG. 4. IFN-g-induced IRF expression by EMSA. Each cell
line was plated at 5 3 105 cells/well in 6-well plates with 0
U/ml, 100 U/ml, or 250 U/ml IFN-g for 2 days. Whole cell ex-
tracts were isolated and incubated with radiolabeled C13
oligomer, which binds both IRF-1 and IRF-2. The samples were
then separated on nondenaturing 4% acrylamide gel and visu-
alized by autoradiography. Cold competitive experiments using
unlabeled C13 oligomer completely eliminated all bands (data
not shown). Similar results were obtained after 3 days of IFN-
g incubation (data not shown).
FIG. 5. IFN-g induced ratio of IRF-1/IRF-2 binding activity by EMSA. Cells were treated with 100 U/ml IFN-g and whole
cell extract isolated as detailed in the Figure 4 legend. (A) Induced IRFs. Extract was incubated at 0°C for 60 min without any
antibody before incubation with radiolabeled C13 oligomer. (B) Separation of IRF-1 and IRF-2 by anti-IRF-2 antibody super-
shift. Extract was incubated at 0°C for 60 min with anti-IRF-2 antibody before incubation with radiolabeled C13 oligomer. Sam-
ples were then run on the same nondenaturing 4% acrylamide gel and visualized by autoradiography. Anti-IRF-1 antibody dem-
onstrated similar results (supershifted bands). (C) Densitometric ratios of IRF-1/IRF-2. Ratios of densitometric values obtained
using NIH imaging software were determined from bands seen on B. Repeated experiments using either or both IRF-1 and IRF-
2 antibody confirmed the relationships seen in B and C.
sponse to IFN-g (Fig. 6). This was observed in repeated ex-
periments whether using IRF-1 antibody, IRF-2 antibody, or
both to determine the IRF-2 binding activity. This pattern con-
tributed to the high IRF-1/IRF-2 ratio in the inhibited cell lines.
Attenuation of IFN-g growth inhibition using IRF-1
antisense oligonucleotide
To confirm the role of IRF-1 in mediating the growth in-
hibitory effect of IFN-g we used IRF-1 AS, which has been
shown to markedly decrease IRF-1 protein by immunoblotting
and IRF-1 mRNA by RT-PCR.(30) To further confirm the abil-
ity of IRF-1 AS to decrease IRF-1 in our system, we assessed
IRF-1 binding activity by EMSA of IFN-g-treated SKBR3 and
MDA436 cells in the presence of IRF-1 AS, NS, or no oligo-
nucleotide. There was a marked decrease in IRF-1 binding ac-
tivity using IRF-1 AS, whether assessed by supershifted IRF-1
protein using IRF-1 Ab or unshifted IRF-1 protein using IRF-
2 Ab, in both MDA436 (Fig. 7A) and SKBR3 (Fig. 7B). Inhi-
bition of IRF-1 binding activity ranged from 43% to 72% vs.
any control, as assessed by densitometry. When used to assess
its effect on IFN-g-mediated growth inhibition, IRF-1 AS sig-
nificantly blocked the growth inhibitory effect of IFN-g in the
MDA436 (Fig. 8A) and MDA468 (Fig. 8B) cell lines at 4–5
days in a dose-related manner. As expected, SKBR3 showed
little growth inhibition by IFN-g, which was unchanged by IRF-
1 AS at the concentrations used (Fig. 8C).
DISCUSSION
In these studies, we demonstrate that IRF-1 is directly re-
lated to the growth inhibitory activity of IFN-g and the IFN-g-
induced ratio of IRF-1 binding activity to IRF-2 binding activ-
ity correlates with this response in human breast carcinoma
cells. This appears to be due to two factors: (1) upregulation of
gene expression of IRF-1 demonstrated by increased mRNA by
RT-PCR and increased IRF-1 binding activity, and (2) de-
creased IRF-2 binding activity in the cell lines that were growth
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FIG. 6. IFN-g-induced change in IRF-1 and IRF-2 binding activity by EMSA. (A) Autoradiograph comparison of samples run
from cells treated with or without IFN-g, using IRF-2 antibody with all extracts to determine IRF-1 binding activity (unsuper-
shifted bands). Results were similar using IRF-1 antibody to determine IRF-1 binding activity (supershifted bands). (B) Densi-
tometric comparison of IRF-1 binding activity. (C) Autoradiograph comparison of samples run from cells treated with or with-
out IFN-g, using IRF-2 antibody with all extracts to determine IRF-2 binding activity (supershifted bands). Results were similar
using IRF-1 antibody to determine IRF-2 binding activity (unsupershifted bands). (D) Densitometric percentage change in IRF-
2 binding activity. All samples were treated, isolated, incubated with antibody and C13 oligomer, run on gels, and autora-
diographed at the same time. Densitometric values were obtained using NIH imaging software on scanned autoradiographs.
inhibited and increased IRF-2 binding activity in the cell line
that was not growth inhibited. These two factors produced the
differences in the IRF-1/IRF-2 ratio observed in these cell lines.
Furthermore, antisense oligonucleotide against IRF-1 signifi-
cantly blocked the growth inhibitory effect of IFN-g on
MDA436 and MDA468 in a dose-related manner, confirming
the role of IRF-1 in mediating IFN-g growth inhibition in these
cell lines.
There have been few studies evaluating the role of IRF-1 and
IRF-2 in human tumor cell response to type I IFN and no stud-
ies before this one to assess the role of IRF-1 and IRF-2 in hu-
man tumor cell response to IFN-g. Jelinek et al.(27) observed a
differential responsiveness to IFN-a in multiple myeloma cell
lines, with four cell lines showing suppression of DNA syn-
thesis by 3H-thymidine incorporation and one showing en-
hanced DNA synthesis. They found no correlation of IRF-1 or
IRF-2 with this difference, and analysis of Stat1, Stat2, and
Stat3 also failed to reveal any differences. The authors also
noted an increase in IRF-2 binding activity in a cell line that
was responsive to IFN-a. However, they studied IFN-a, not
IFN-g, after only 2 h of stimulation, and noted that IFN-a was
only modestly effective at inducing IRF-1 binding activity in
any of their cell lines. IRF-2 binding activity dominated in the
absence or presence of IFN-a in the growth-suppressed and
growth-enhanced cell lines. Fischer et al.(28) tried to correlate
actual clinical responsiveness to IFN-a and IFN-b with IRF-1
and IRF-2 expression in patients being treated for chronic
myelogenous leukemia (CML) and found no correlations. How-
ever, they exclusively evaluated mRNA expression by North-
ern analysis. They did note that both IRF-1 and IRF-2 mRNA
were increased in mononuclear cells from CML patients both
in vitro and after subcutaneous administration of IFN-a.
We and others have found that endogenous IFN-g plays a
substantial role in suppression of growth of tumors in syngeneic
mice. In previous experiments, we have shown that a single ad-
ministration of anti-IFN-g antibody to MCA101 and MCA105
tumor-bearing syngeneic mice caused tumor cells to grow faster






































FIG. 7. Confirmation of reduction of IRF-1 binding activity
by IRF-1 antisense oligonucleotide. Cells were preincubated
with the indicated oligonucleotide, or no oligonucleotide, in re-
duced serum medium (Opti-MEM) for 4 h, then incubated in
the presence of 100 U/ml IFN-g. Cells were harvested for
EMSA after 2 days. Bands shown here are all IRF-1, and each
row of bands is from the same gel and autoradiograph. IRF-1
binding activity was decreased by 43% to 72% compared with
any control, as assessed by densitometry. (A) MDA436. (B)
SKBR3.
FIG. 8. IRF-1 antisense oligonucleotide attenuation of IFN-
g growth inhibition. Cells (in triplicate samples) were preincu-
bated with the indicated oligonucleotide, or no oligonucleotide,
in reduced serum medium (Opti-MEM) for 4 h, then incubated
in the presence or absence of 100 U/ml IFN-g. MTT was used
to assay viable cell number after 4–5 days. Absorbances were
normalized, with unstimulated cells equal to 1, to assist with
comparison. (A) MDA436. (B) MDA468. (C) SKBR3.
have demonstrated that B16.F10 tumors grow much more
rapidly in syngeneic IFN-g knockout mice.(26) Prior studies
have shown that at least a major portion of the effect of en-
dogenous IFN-g is directed at the tumor cells rather than host
immune cells.(34,36) These data demonstrate that in vivo tumors
may be subject to a longer term, more chronic, local environ-
ment rich in IFN-g and that their response or lack of response
to this chronic presence may play a role in the behavior of, or
even the development of, malignancy. Indeed, in mice, we have
shown that IRF-2 overexpression by gene transfer into B16.F10
cells causes faster tumor growth in syngeneic mice vs. un-
transfected and empty vector-transfected controls. This differ-
ence was almost completely abolished in IFN-g knockout mice,
implying that resistance to chronic endogenous IFN-g by IRF-
2 expression at the level of the tumor led to this more rapid
growth.(26)
There is a correlation between the induced ratio of IRF-
1/IRF-2 and growth inhibition by chronic IFN-g in human tu-
mor cell lines, and there is a role for endogenous IFN-g in tu-
mor suppression. This leads us to postulate that analysis of
IRF-1 and IRF-2 expression by tumor cells in humans may cor-
relate with tumor behavior because of resistance to endogenous
IFN-g. The aggressiveness of a tumor may depend partly on its
ability to resist the tumor-suppressive effects of IFN-g. More-
over, analysis of IRF-1 and IRF-2 expression may determine
candidacy for treatment with exogenous IFN-g or other cyto-
kines, including TNF-a and IL-12, based on the fact that IFN-
g has been found to play a role in the toxic and antitumor 
effects of other cytokines as well.(34,36,37) Our initial immuno-
histochemical studies of archival human breast cancer speci-
mens show a correlation between significant prognostic factors
and the loss of IRF-1 expression and gain of IRF-2 expres-
sion.(24) For human melanoma, there is a correlation between
the loss of IRF-1 expression and prognosis. IRF-2 expression
was not as clearly involved. Malignant melanoma thickness,
stage, and histomorphology all correlate with the level of IRF-
1 expression, and the loss of IRF-1 expression appears to cor-
relate with tumor progression.(23)
We did not expect to find that IRF-2 binding activity, as as-
sessed by EMSA, decreased in three of the cell lines on incu-
bation with IFN-g, as previous studies have shown that IRF-2
mRNA expression is increased by IFNs and IRF-1. However,
most studies evaluated IRF-2 mRNA production, not IRF-2 ac-
tivity by EMSA, and the stimulating agent was more often virus
or type I IFN rather than IFN-g.(17,38) Finally, although in-
creased IRF-1 binding activity has been assessed in multiple
cell lines, very few cell lines have been assessed for increase
in IRF-2 binding activity. In our RT-PCR experiments, we
showed barely detectable IRF-2 mRNA induced by IFN-g, usu-
ally at 24 h, which was not detectable in unstimulated cells.
However, our RT-PCR was not sufficiently sensitive to detect
IRF-2 in unstimulated cells, where it was found in every cell
line by EMSA. A binding sequence for IRF has been found in
the promoter region of the human IRF-2 gene, and IRF-1 has
been found to upregulate downstream expression at that pro-
moter region.(39) It may be that IFN-g treatment and subsequent
increased IRF-1 lead to increased IRF-2 mRNA expression, and
that modification occurs after transcription in the three growth-
inhibited cell lines, leading to decreased IRF-2 binding activ-
ity. This could include posttranscriptional or posttranslational
changes or both. Finally, IRF-2 binding activity may be influ-
enced by other factors (such as protein-protein interactions) that
prevent IRF-2 protein from binding DNA. The differential reg-
ulation of IRF-1 and IRF-2 binding activity at the transcrip-
tional, translational, functional level despite similar proximal
IFN-g signaling appears to be a key checkpoint for growth in-
hibition by IFN-g and will require further study.
To directly implicate the IRF-1/IRF-2 ratio in the growth in-
hibitory effects of IFN-g in these cell lines, we chose to block
IRF-1 effects with antisense oligonucleotides. We used an an-
tisense oligonucleotide (IRF-1 AS) already known to decrease
IRF-1 protein by Western blot(30) and further confirmed that
this oligonucleotide can decrease IRF-1 binding activity in
breast cancer cells (Fig. 7). The effects of IRF-1 AS in MDA436
and MDA468 were significant because they were sequence spe-
cific and dose dependent and caused a positive biologic effect,
as demonstrated by reversal of growth inhibition in the pres-
ence of IFN-g. We were unable to obtain an effective IRF-2
AS.
IRF-1 and IRF-2 appear to play a significant role in IFN-g-
mediated growth inhibition. Presumably this is due to upregu-
lation of certain genes by IRF-1 and downregulation, or block-
ade of upregulation, of the same genes by IRF-2. Some of the
genes upregulated by IRF-1 implicated in growth inhibition in-
clude the protein kinase PKR,(40) 29,59-oligoadenylate syn-
thetase,(41) and lysyl oxidase.(42) Genes with binding sequences
for IRFs in their promoter region include p53 and cyclin D1,(41)
although no studies have been performed to prove that these
genes are actually upregulated by IRF-1. We have preliminary
evidence demonstrating that apoptosis may have a role in
growth inhibition found in MDA468 because MDA468 shows
markedly increased apoptosis in the presence of IFN-g, whereas
SKBR3 shows no evidence of apoptosis. Clearly, the down-
stream effects of IRF-1 are an area for future study.
In summary, we have found a correlation of the induced ra-
tio of IRF-1/IRF-2 by IFN-g with the growth inhibitory re-
sponse to IFN-g in vitro in four human breast carcinoma cell
lines. IRF-1 mRNA and binding activity increase in correlation
with growth inhibition by IFN-g. IRF-2 binding activity actu-
ally decreases in response to IFN-g in inhibited cells, whereas
it increases in the uninhibited cell line. IRF-1 AS attenuated
IFN-g growth inhibition in the majority of IFN-g sensitive cell
lines, further supporting the role of IRF-1 in IFN-g growth sup-
pression. Given our understanding from previous data regard-
ing endogenous IFN-g in mice, analysis of the ratio of IRF-
1/IRF-2 may help determine prognosis, as well as response to
exogenous IFN-g or other cytokines, in human cancer.
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